Terminated PHASE1/PHASE2 INTERVENTIONAL NCT01712646

Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

The Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial

Sponsor: National Institute of Mental Health (NIMH)

Conditions Childhood Onset Psychotic Disorders Schizophrenia

Interventions Intranasal Oxytocin

Updated 7 times since 2017 Last updated: Jul 6, 2017 Started: Oct 5, 2012 Primary completion: Jun 20, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Institute of Mental Health (NIMH)

See all terminations from National Institute of Mental Health (NIMH)

Other Childhood Onset Psychotic Disorders trials with similar outcome

Browse all Childhood Onset Psychotic Disorders trials

This PHASE1/PHASE2 trial investigates Childhood Onset Psychotic Disorders and Schizophrenia and is currently terminated or withdrawn. National Institute of Mental Health (NIMH) leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
Aug 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Aug 2017 [monthly]

Terminated PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1_PHASE2

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States